Article
Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?
Pharmacogenomics - 1 Jun 2014
Salazar Juliana, Moya Patricia, Altés Albert, Díaz-Torné César, Casademont Jordi, Cerdà-Gabaroi Dacia, Corominas Hèctor, Baiget Montserrat
Abstract excerpt
BACKGROUND: Methotrexate (MTX) is the first-line treatment option for newly diagnosed rheumatoid arthritis (RA) patients. However, 50-70% of the patients respond to treatment and 30% suffer toxicity. AIM: To identify pharmacogenetic markers of outcome in RA patients treated with MTX. PATIENTS & METHODS: We analyzed 27 genetic variants in DHFR, TYMS, MTHFR, ATIC and CCND1 genes. RESULTS: We included 124 RA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
